Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and autologous stem cell transplantation (ASCT) for relapsed chemosensitive diffuse large B-Cell lymphoma (DLBCL):: Impact of the IPI and PET status

被引：4

作者：

Alousi, Amin M. ^{[1
]}

Hosing, Chitra ^{[1
]}

Saliba, Rima M. ^{[1
]}

Valverde, Rosainar B. ^{[1
]}

Maadani, Farzaneh ^{[1
]}

Korbling, Martin ^{[1
]}

Okoroji, Grace J. ^{[1
]}

Fayad, Luis E. ^{[2
]}

Stachowiak, Anne M. ^{[3
]}

Erwin, William D. ^{[4
]}

Anderlini, Paolo ^{[1
]}

de Lima, Marcos J. ^{[1
]}

Giralt, Sergio A. ^{[1
]}

Popat, Uday R. ^{[1
]}

Kebriaei, Partow ^{[1
]}

Ueno, Naoto T. ^{[1
]}

McLaughlin, Peter W. ^{[2
]}

Pro, Barbara ^{[2
]}

Wang, Michael ^{[2
]}

Rodriguez, Alma ^{[2
]}

Hagemeister, Fredrick B. ^{[2
]}

Macapinlac, Homer A. ^{[5
]}

Podoloff, Donald A. ^{[5
]}

Champlin, Richard E. ^{[1
]}

Khouri, Issa F. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] MD Anderson Canc Ctr, Lymphoma, Houston, TX USA

[3] MD Anderson Canc Ctr, Diag Imaging, Houston, TX USA

[4] MD Anderson Canc Ctr, Imaging Phys, Houston, TX USA

[5] MD Anderson Canc Ctr, Nucl Med, Houston, TX USA

来源：

关键词：

D O I：

10.1182/blood.V110.11.620.620

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

620

引用

页码：191A / 192A

页数：2